Therefore, our results corroborate previous findings and suggest that the Luminal A subtype of ER+/HER2+ breast cancer may benefit from AI plus anti-HER2 therapy alone, potentially achieving long-term survival without the need for chemotherapy. This evidence concerns the gene ESR1 and breast cancer.